Biomarin Pharmaceutical Inc
XBER:BM8

Watchlist Manager
Biomarin Pharmaceutical Inc Logo
Biomarin Pharmaceutical Inc
XBER:BM8
Watchlist
Price: 50.68 EUR 0.12% Market Closed
Market Cap: 9.3B EUR

Gross Margin
Biomarin Pharmaceutical Inc

81.3%
Current
79%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
81.3%
=
Gross Profit
2.5B
/
Revenue
3.1B

Gross Margin Across Competitors

No Stocks Found

Biomarin Pharmaceutical Inc
Glance View

In the bustling hub of biotechnology innovation, BioMarin Pharmaceutical Inc. stands as a notable entity, driven by its mission to transform medical research into meaningful treatments for patients worldwide. Founded in 1997 and headquartered in San Rafael, California, BioMarin has carved a niche in the competitive landscape by specializing in therapies for rare genetic diseases. The company navigates the arduous and often uncertain path of drug development by targeting serious, and typically overlooked, medical conditions. BioMarin's expertise lies in leveraging cutting-edge genetic knowledge and technological advances to develop biopharmaceuticals that address unmet medical needs. This focus not only guides its scientific explorations but also informs its business strategy, where the development of drugs like Vimizim and Palynziq for conditions such as Morquio A syndrome and phenylketonuria, respectively, have made substantial impacts. BioMarin's revenue stream is predominantly fueled by these specialized therapies that cater to niche markets, with patients who often have limited treatment alternatives. Unlike traditional pharmaceuticals, BioMarin's portfolio is characterized by its strategic focus on orphan diseases, allowing it to capitalize on regulatory incentives designed to encourage the development of treatments for rare disorders. This approach provides market exclusivity and premium pricing potential, contributing to its financial robustness. Additionally, BioMarin's continuous investment in research and development ensures a dynamic pipeline aiming to introduce new innovations. This cycle of discovery and commercialization effectively sustains its growth trajectory, allowing BioMarin to not only thrive financially but also deliver on its commitment to improve patient lives with ultra-rare conditions.

BM8 Intrinsic Value
64.44 EUR
Undervaluation 21%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
81.3%
=
Gross Profit
2.5B
/
Revenue
3.1B
What is the Gross Margin of Biomarin Pharmaceutical Inc?

Based on Biomarin Pharmaceutical Inc's most recent financial statements, the company has Gross Margin of 81.3%.

Back to Top